425 related articles for article (PubMed ID: 18775201)
1. Treatment of invasive candidal infections: systematic review and meta-analysis.
Gafter-Gvili A; Vidal L; Goldberg E; Leibovici L; Paul M
Mayo Clin Proc; 2008 Sep; 83(9):1011-21. PubMed ID: 18775201
[TBL] [Abstract][Full Text] [Related]
2. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.
Kullberg BJ; Sobel JD; Ruhnke M; Pappas PG; Viscoli C; Rex JH; Cleary JD; Rubinstein E; Church LW; Brown JM; Schlamm HT; Oborska IT; Hilton F; Hodges MR
Lancet; 2005 Oct 22-28; 366(9495):1435-42. PubMed ID: 16243088
[TBL] [Abstract][Full Text] [Related]
3. Severe Candida albicans panophthalmitis treated with all available and potentially effective antifungal drugs: fluconazole, liposomal amphotericin B, caspofungin, and voriconazole.
Manfredi R; Sabbatani S
Scand J Infect Dis; 2006; 38(10):950-1. PubMed ID: 17008248
[TBL] [Abstract][Full Text] [Related]
4. [New developments in antifungal therapy: fluconazole, itraconazole, voriconazole, caspofungin].
van 't Wout JW; Kuijper EJ; Verweij PE; Kullberg BJ
Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1679-84. PubMed ID: 15453120
[TBL] [Abstract][Full Text] [Related]
5. Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis.
Mills EJ; Perri D; Cooper C; Nachega JB; Wu P; Tleyjeh I; Phillips P
Ann Clin Microbiol Antimicrob; 2009 Jun; 8():23. PubMed ID: 19558681
[TBL] [Abstract][Full Text] [Related]
6. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.
Queiroz-Telles F; Berezin E; Leverger G; Freire A; van der Vyver A; Chotpitayasunondh T; Konja J; Diekmann-Berndt H; Koblinger S; Groll AH; Arrieta A;
Pediatr Infect Dis J; 2008 Sep; 27(9):820-6. PubMed ID: 18679151
[TBL] [Abstract][Full Text] [Related]
7. Antifungal agents in children.
Steinbach WJ
Pediatr Clin North Am; 2005 Jun; 52(3):895-915, viii. PubMed ID: 15925667
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs.
Wang JF; Xue Y; Zhu XB; Fan H
Eur J Clin Microbiol Infect Dis; 2015 Apr; 34(4):651-9. PubMed ID: 25502737
[TBL] [Abstract][Full Text] [Related]
9. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
Ziakas PD; Kourbeti IS; Mylonakis E
Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
[TBL] [Abstract][Full Text] [Related]
10. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
Keating G; Figgitt D
Drugs; 2003; 63(20):2235-63. PubMed ID: 14498760
[TBL] [Abstract][Full Text] [Related]
11. Newer antifungal agents micafungin and voriconazole for fungal infection prevention during hematopoietic cell transplantation: a meta-analysis.
Xu SX; Shen JL; Tang XF; Feng B; Xu HQ
Eur Rev Med Pharmacol Sci; 2016; 20(2):381-90. PubMed ID: 26875911
[TBL] [Abstract][Full Text] [Related]
12. Antifungal resistance: the clinical front.
Perfect JR
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 13):15-22. PubMed ID: 15682590
[TBL] [Abstract][Full Text] [Related]
13. Caspofungin: new indication. No progress in invasive candidiasis.
Prescrire Int; 2004 Apr; 13(70):48-9. PubMed ID: 15148956
[TBL] [Abstract][Full Text] [Related]
14. Voriconazole for candidosis: an important addition?
Graybill JR
Lancet; 2005 Oct 22-28; 366(9495):1413-4. PubMed ID: 16243074
[No Abstract] [Full Text] [Related]
15. Anidulafungin in the treatment of patients with invasive candidiasis.
Kett DH; Cubillos GF
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S99-S102. PubMed ID: 19013348
[TBL] [Abstract][Full Text] [Related]
16. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia.
Jørgensen KJ; Gøtzsche PC; Dalbøge CS; Johansen HK
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD004707. PubMed ID: 24563222
[TBL] [Abstract][Full Text] [Related]
17. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.
Cross SA; Scott LJ
Drugs; 2008; 68(15):2225-55. PubMed ID: 18840009
[TBL] [Abstract][Full Text] [Related]
18. Combination antifungal therapy: where are we now, and where are we going?
Marr K
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):24-9. PubMed ID: 15651179
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of amphotericin B, azoles and echinocandins in the treatment of candidemia and invasive candidiasis: A systematic review and network meta-analysis.
Demir KK; Butler-Laporte G; Del Corpo O; Ekmekjian T; Sheppard DC; Lee TC; Cheng MP
Mycoses; 2021 Sep; 64(9):1098-1110. PubMed ID: 33894072
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
Almyroudis NG; Sutton DA; Fothergill AW; Rinaldi MG; Kusne S
Antimicrob Agents Chemother; 2007 Jul; 51(7):2587-90. PubMed ID: 17452481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]